Sign up for our newsletter
2026 NCCN bladder cancer update
Practical takeaways from new NCCN guidance
Risk and anticoagulation at EHA2026
VTE models, ADAPT-BLEED, and DOAC vs warfarin
Linvoseltamab in AL amyloidosis
Rapid, deep responses in early-phase study
Anselamimab in AL: Phase 3 data
κ subgroup benefit observed in CARES trial
Nivolumab: No DFS benefit in NSCLC
Phase 3 EA5142 results presented at ASCO 2026
No OS detriment with durvalumab
POTOMAC shows stable OS and QoL
Read more medical news stories here.